Penggunaan Produk Biosimilar pada Transplantasi Ginjal
DOI:
https://doi.org/10.55175/cdk.v48i11.151Kata Kunci:
biosimilar, transplantasi ginjal, rejeksiAbstrak
Transplantasi ginjal sering menimbulkan rejeksi, oleh karenanya diperlukan obat-obatan imunosupresan sebelum, saat, dan setelah transplantasi ginjal. Terapi imunosupresan pada transplantasi ginjal terdiri dari terapi induksi, pemeliharaan awal, dan pemeliharaan jangka panjang. Beberapa produk biosimilar dapat digunakan untuk terapi rejeksi pada transplantasi ginjal.
Kidney transplantation often results in rejection; it is necessary to give immunosuppressant drugs before, during, and after kidney transplantation. Immunosuppressant therapy in kidney transplantation consists of induction therapy, early maintenance, and long-term maintenance. Several biosimilar products can be used for immunosuppressant in kidney transplants.
Unduhan
Referensi
Indonesia Renal Registry. 6th Annual report of Indonesian renal registry [Internet]. 2013 [cited 2021 April 21]. Available from: https://www.indonesianrenalregistry.org/data/INDONESIAN%20RENAL%20REGIS TRY%202013.pdf
Indonesia Renal Registry. 11th report of Indonesian renal registry [Internet]. 2013 [cited 2021 April 21]. Available from: https://www.indonesianrenalregistry.org/data/IRR%202018.pdf
Riskesdas [Internet]. 2013. [cited 2021 April 21]. Available from: https://www.pusdatin.kemkes.go.id/resources/download/general/Hasil%20Riskesdas %202013.pdf
Konsensus transplantasi ginjal PERNEFRI [Internet]. 2013. Available from: https://www.pernefri.org/konsensus/Konsensus%20Transplant%20-%20Isi.pdf
Wish JB. Biosimilars—Emerging role in nephrology. Clin J Am Soc Nephrol. 2019;14:1391–8.
Kapic E, Becic F, Kusturica J. Basiliximab, mechanism of action and pharmacological properties. Med Arh. 2004;58(6):373-6.
Chapman TM, Keating GM. Basiliximab a review of its use as induction therapy in renal transplantation. Drugs 2003;63(24):2803-35.
Keown PA, Balshaw R, Khorasheh S, Chong M, Marra C, Kalo Z, et al. Meta-analysis of basiliximab for immunoprophylaxis in renal transplantation. Biodrugs 2003;17(4):271-9.
Kamar N, Lepage B, Couzi L, Albano L, Durrbach A, Pernin V, et al. A randomized prospective study comparing anti–T-lymphocyte Igs to basiliximab in highly sensitized kidney transplant patients. Kidney International Reports 2020;5:1207–17.
Kim SJ, Rhu J, Yoo H, Kim K, Lee KW, Park JB. Outcome comparison between low-dose rabbit anti-thymocyte globulin and basiliximab in low-risk living donor kidney transplantation. J Clin Med. 2020;9:1320.
Belatacept (Nulojix™) national drug monograph [Internet]. 2012 April. [cited 2021 April 21]. Available from: https://www.pbm.va.gov/PBM/clinicalguidance/drugmonographs/BelatacpetNulojixD rugMonograph.pdf
Hardinger KL, Sunderland D, Wiederrich JA. Belatacept for the prophylaxis of organ rejection in kidney transplant patients: An evidence-based review of its place in therapy. Int J Nephrol Renovasc Dis. 2016;9:139–50.
Florman S, Becker T, Bresnahan B, Chevaile-Ramos A, Carvalho D, Grannas G, et al. Efficacy and safety outcomes of extended criteria donor kidneys by subtype: Subgroup analysis of BENEFIT-EXT at 7 Years After Transplant. Am J Transplantation 2017;17:180–90.
Unduhan
Diterbitkan
Cara Mengutip
Terbitan
Bagian
Lisensi
Hak Cipta (c) 2021 Cermin Dunia Kedokteran
Artikel ini berlisensi Creative Commons Attribution-NonCommercial 4.0 International License.
